A new medicine for severe breathing problems in ARDS
Official title: Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier
Funded at Illexcor Therapeutics, LLC · NIH-11145630 · Data updated 2026-11-12
This research is developing a new medicine to help patients with severe acute respiratory distress syndrome (ARDS) get enough oxygen.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Illexcor Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | January 1, 2021 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $798,351 |
| NIH project number | 5R44HL156334-04 |
| Project ID | NIH-11145630 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is focused on developing a treatment for individuals experiencing severe acute respiratory distress syndrome (ARDS) and profound hypoxemia.
✕Less likely to help
Patients with mild breathing issues or those whose respiratory failure is due to heart problems may not benefit from this specific approach.
What this research studies
Acute respiratory distress syndrome (ARDS) is a serious condition where your lungs cannot provide enough oxygen to your body, leading to severe breathing difficulties. Current treatments, like extra oxygen and breathing machines, have limits and haven't significantly improved survival rates for many years. This project aims to create a new medication that works by helping your red blood cells carry and deliver oxygen more effectively to your tissues. The hope is that this new medicine could prevent critical organ damage and improve outcomes for those suffering from severe ARDS.
Why it matters
Potential benefit: If successful, this new medication could significantly improve oxygen delivery to vital organs and reduce the high mortality rate associated with severe ARDS.
How similar studies have gone: Current supportive therapies for ARDS have not substantially improved mortality in decades, suggesting this novel pharmacologic approach is largely untested in this specific context.
Where this research is happening
-
Illexcor Therapeutics, LLC
Richmond, United States Active
Researchers
- Principal investigator: Light, David Richard — Illexcor Therapeutics, LLC
- Study coordinator: Light, David Richard
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Lipid-gene Profiles in Septic ARDS
A Mayo Clinic team is studying how dysfunctional HDL in sepsis relates to different ARDS patient outcomes, aiming to find features that could guide better treatment.
-
Improving blood vessel repair after pediatric ARDS
Aims to better repair the lungs of children who have ARDS by delivering targeted therapy to lung blood vessels using tiny nanoparticles.
-
NOX4 links to ARDS risk and progression
Aims to understand how NOX4-driven cell damage may make some adults with ARDS worse off and how this could lead to earlier, targeted care.
-
Leading causes of death in alcoholic ARDS patients using clinical data
This project uses big clinical data and AI to find the main factors that cause death in adults with ARDS who have alcohol use issues, aiming to improve understanding and care.
-
Targeting aging-related blood vessel injury to prevent ARDS in older lungs
Aims to find ways to protect lung blood vessels in older adults to prevent dangerous lung swelling (ARDS).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.